^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

TP53 (Tumor protein P53)

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
3d
SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer. (PubMed, Prostate)
This is the largest cohort of men with SPOP mutations, including those with de novo mHSPC treated with an ARPI, reported to date. Further prospective study of SPOP-mutated PC may help guide which patients with de novo mHSPC may either benefit from or can forego the addition of chemotherapy.
Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • SPOP (Speckle Type BTB/POZ Protein)
|
PTEN mutation
|
docetaxel
3d
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial. (PubMed, JAMA Oncol)
The final analysis of the BRIGHT-2 randomized clinical trial confirms improved PFS with the addition of bireociclib to fulvestrant, with manageable safety as a treatment option for patients with HR-positive, ERBB2-negative ABC with progression after prior endocrine therapy. ClinicalTrials.gov Identifier: NCT05077449.
Clinical • P3 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HR positive • HER-2 negative • EGFR positive
|
fulvestrant • Xuan Yue Ning (bireociclib)
3d
A personalized therapeutic approach for liver cancers expressing the African-centric P47S Variant of TP53. (PubMed, Mol Cancer Res)
We identify the microtubule targeting agents lexibulin, colchicine, and combretastatin A-4 as three compounds that bind to the colchicine-binding pocket of the a/b tubulin dimer, and which show increased efficacy in a P47S liver cancer cell line compared to parental cells with WT p53. We find evidence for an unusual mechanism underlying this increased efficacy: our data indicate that the P47S variant shows increased ability to bind to the peptidyl-prolyl isomerase PIN1; this leads to decreased PIN1-cyclin D1 complexes in P47S cells, along with increased cell cycle arrest in response to lexibulin. IMPLICATIONS: These findings support the growing literature that particular mutant forms of TP53 may have specific therapeutic vulnerabilities that can be targetable; improved understanding of these unique vulnerabilities can lead to improved understanding of p53 function.
Journal
|
TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
|
TP53 mutation • TP53 wild-type
|
lexibulin (CYT997)
4d
Hodgkin Variant Richter's Transformation in the Absence of Classical Risk Factors: A Rare Case With Spinal Manifestation. (PubMed, Cureus)
After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition. HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion.
Journal
|
TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
|
TP53 mutation • IGH mutation
|
doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
4d
Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer. (PubMed, iScience)
Whereas p53 KO organoids are sensitive to the combined inhibition of ATM and PARP, acid adaptation partially rescues this phenotype, increasing treatment resistance in a manner partially restored by the combined inhibition of pH-regulatory transporters. We conclude that p53 loss rewires acid-base homeostasis and that microenvironment acidity limits treatment response in p53-deficient PDAC, possibly by increasing cancer cell pH homeostasis capacity.
Journal • PARP Biomarker
|
TP53 (Tumor protein P53) • ATR (Ataxia telangiectasia and Rad3-related protein) • CHEK1 (Checkpoint kinase 1)
|
TP53 mutation
4d
Comprehensive genomic analysis of non-BRCA familial breast cancer in an Arab population. (PubMed, NPJ Breast Cancer)
PRS assessment identified four PRSs with good discriminatory power (AUC > 0.690), with PGS003738 showing the highest performance (AUC = 0.702, top decile OR = 3.57). These findings highlight the need for population-specific genetic studies to improve breast cancer risk stratification in Arab populations.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1)
|
BRCA2 mutation • BRCA1 mutation
4d
IHC p53 Performance in NordiQC: Recalibration of IHC Assays is Needed. (PubMed, Appl Immunohistochem Mol Morphol)
The findings underscore an urgent need to recalibrate p53 IHC protocols, with a special focus on improving analytical sensitivity and ensuring consistent use of both internal and external controls. Aligning IHC assays calibrated to identify the full spectrum of TP53 mutations, including those that result in absent and wild-type patterns, can significantly enhance the diagnostic accuracy of p53 IHC.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
4d
Absence of CD38 Expression in Mantle Cell Lymphoma Correlates with Distinct Pathological and Genetic Features. (PubMed, Hum Pathol)
Biologically, CD38-negative cnMCLs appear to be more likely driven by CD38-independent, alternative signaling pathways. From a clinical perspective, identification of CD38-negative cnMCLs by flow cytometry may help recognizing patients at increased risk for adverse genetic features, including TP53 inactivation.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IGH (Immunoglobulin Heavy Locus) • KMT2D (Lysine Methyltransferase 2D) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TP53 mutation • ATM mutation • IGH mutation
4d
High diffuse bone marrow uptake in 18F-FDG PET/CT may reflect the diverse mutational characteristics of multiple myeloma. (PubMed, Korean J Intern Med)
Patients with high DU showed diverse mutational characteristics, which may reflect the heterogeneous nature of MM and contribute to inferior survival outcomes.
Retrospective data • Journal
|
TP53 (Tumor protein P53) • ATM (ATM serine/threonine kinase) • HUWE1 (HECT UBA And WWE Domain Containing E3 Ubiquitin Protein Ligase 1) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1)
|
TP53 mutation • ATM mutation
4d
Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival. (PubMed, JCO Precis Oncol)
Young patients with DPM have strong personal and family histories of cancer, and heterogeneous somatic and germline alterations, indicating divergent underlying biology. With the increasing prevalence of young adults with cancers, mesotheliomas, although uncommon, should be on the differential for patients even without asbestos exposure history in this age group.
Journal • Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
TMB-L
4d
Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study. (PubMed, JCO Clin Cancer Inform)
This AI-augmented study demonstrates the feasibility and scalability of combining NLP-derived insights with OMOP-standardized structured data to generate reproducible RWE in hematology. Our results highlight an elderly CLL population with significant comorbidities and a shift toward targeted therapies. While treatment patterns aligned with guidelines, data quality depended on source documentation accessibility. Improved integration of molecular testing into electronic health records is essential for enhancing clinical decision making, patient outcomes, and future research.
Retrospective data • Journal • Real-world evidence
|
TP53 (Tumor protein P53)
4d
Targeted NMR signal enhancement of RNA by site-directed bis-nitroxide labeling. (PubMed, Proc Natl Acad Sci U S A)
The selectivity of polarization transfer within the RNA duplex relative to the surrounding environment could be tuned by matrix deuteration, while doping with paramagnetic metal ions accelerated polarization build-up times, with CuII proving more efficient than GdIII. This work establishes bisnitroxide-based SDSL as a powerful approach for targeted DNP of nucleic acids, enabling high-sensitivity studies of nucleic acids at concentrations ≤40 µm and paves the way for structural investigations of microRNA-mRNA interactions in cells.
Journal
|
TP53 (Tumor protein P53) • MIR34A (MicroRNA 34a-5p) • SIRT1 (Sirtuin 1)